Medtech titan Boston Scientific (NYSE:BSX) won European regulatory approval for its Rebel bare-metal stent, a drug-free version of its Promus Premier device.
The next-generation Rebel coronary stent is made from the same platinum chromium material and is based on the same architecture as the Promus Premier, which is part of Boston Scientific’s lager Promus portfolio of proprietary stent technology.
"Boston Scientific is committed to advancing cardiology and providing the best treatment options for all patients with coronary artery disease," interventional cardiology president Kevin Ballinger said in prepared remarks. "This includes innovating and improving the performance of bare metal stent technology to enhance patient outcomes."
The Rebel stent system is not yet on the shelves in the U.S., but has investigational device exemption to undergo human clinical studies, Boston Scientific noted.
The device maker has had some other recent wins in its stent technology, including last month’s E.U. approval for its WallFlex esophageal stent and the October 2013 launch of the MAJESTIC clinical trial of the Innova drug-eluting stent for treatment of blocked arteries above the knee
There have also been some recent snags, including the re-emergency of stent shrinkage concerns during what was otherwise a stalemate between Boston Scientific’s Promus Element and Medtronic’s (NYSE:MDT) Resolute DES next-generation drug-eluting stents.
BSX shares were pretty flat today, slide by 0.4% to trade at $12.82 as of about 11:55 a.m. The stock has gained 7% since the start of the year.
